News Releases

- Inaugural event to feature industry leaders from pharmaceutical, biotechnology and medical device companies with a focus on therapeutics

- Leading institutional investors and key company executives will be in attendance

- Discussions to include potential impact from changing industry dynamics and expectations around a Trump presidency

- Inaugural event to feature industry leaders from pharmaceutical, biotechnology and medical device companies with a focus on therapeutics

- Leading institutional investors and key company executives will be in attendance

- Discussions to include potential impact from changing industry dynamics and expectations around a Trump presidency

- At 335 feet, the BMO Harris Financial Center will be one of the tallest office towers in Milwaukee.

- Reinforces BMO's commitment to the economic development of the city, and adds to the momentum of Milwaukee's downtown renaissance.

Financial Results Highlights:

Fourth Quarter 2016 Compared with Fourth Quarter 2015:

- Net income of $1,345 million, up 11%; adjusted net income(1) of $1,395 million, up 10%

- EPS(2) of $2.02, up 10%; adjusted EPS(1,2) of $2.10, up 11%

- ROE of 13.8%, compared with 12.9%; adjusted ROE(1) of 14.4%, compared with 13.5%

- Provisions for credit losses of $174 million, compared with $128 million

- Common Equity Tier 1 Ratio of 10.1%

- Dividend increased by $0.02 from the preceding quarter to $0.88

Fiscal 2016 Compared with Fiscal 2015:

- Net income of $4,631 million, up 5%; adjusted net income(1) of $5,020 million, up 7%

- EPS(2) of $6.92, up 5%; adjusted EPS(1,2) of $7.52, up 7%

- ROE of 12.1%, compared with 12.5%; adjusted ROE(1) of 13.1%, compared with 13.3%

- Provisions for credit losses of $815 million, compared with $612 million

- Annual dividends paid per share of $3.36 compared to $3.20, an increase of $0.16 or 5%